Esperion Therapeutics (ESPR) Competitors $1.40 -0.02 (-1.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.40 0.00 (0.00%) As of 08/1/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR vs. MLYS, NRIX, SNDX, MENS, IOVA, CRON, XERS, NUVB, TRVI, and QUREShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Mineralys Therapeutics (MLYS), Nurix Therapeutics (NRIX), Syndax Pharmaceuticals (SNDX), Jyong Biotech (MENS), Iovance Biotherapeutics (IOVA), Cronos Group (CRON), Xeris Biopharma (XERS), Nuvation Bio (NUVB), Trevi Therapeutics (TRVI), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Its Competitors Mineralys Therapeutics Nurix Therapeutics Syndax Pharmaceuticals Jyong Biotech Iovance Biotherapeutics Cronos Group Xeris Biopharma Nuvation Bio Trevi Therapeutics uniQure Mineralys Therapeutics (NASDAQ:MLYS) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Which has stronger earnings and valuation, MLYS or ESPR? Esperion Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.73-3.66Esperion Therapeutics$332.31M0.84-$51.74M-$0.80-1.75 Is MLYS or ESPR more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -59.03%. Esperion Therapeutics' return on equity of -0.91% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -71.15% -65.71% Esperion Therapeutics -59.03%-0.91%-29.47% Do insiders & institutionals hold more shares of MLYS or ESPR? 84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 25.6% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 1.7% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer MLYS or ESPR? Mineralys Therapeutics currently has a consensus price target of $32.25, suggesting a potential upside of 136.09%. Esperion Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 400.00%. Given Esperion Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Esperion Therapeutics is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Esperion Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility & risk, MLYS or ESPR? Mineralys Therapeutics has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Does the media favor MLYS or ESPR? In the previous week, Esperion Therapeutics had 3 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 12 mentions for Esperion Therapeutics and 9 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.51 beat Esperion Therapeutics' score of 0.28 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryEsperion Therapeutics beats Mineralys Therapeutics on 11 of the 15 factors compared between the two stocks. Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$281.44M$2.46B$5.48B$9.51BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-1.758.9728.6723.80Price / Sales0.84437.63373.9066.58Price / Cash59.10157.7635.4557.96Price / Book-0.714.838.275.55Net Income-$51.74M$31.62M$3.24B$259.03M7 Day Performance-7.28%-5.28%-3.69%-4.59%1 Month Performance21.74%4.38%4.33%4.46%1 Year Performance-32.04%-2.49%25.95%18.03% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics4.0284 of 5 stars$1.40-1.4%$7.00+400.0%-35.8%$281.44M$332.31M-1.75200News CoverageAnalyst RevisionMLYSMineralys Therapeutics2.558 of 5 stars$13.62-4.3%$32.25+136.8%+13.4%$887.75MN/A-3.6528News CoverageInsider TradeNRIXNurix Therapeutics2.5151 of 5 stars$11.25+0.4%$29.31+160.6%-48.6%$860.06M$54.55M-4.31300News CoverageAnalyst ForecastSNDXSyndax Pharmaceuticals3.5579 of 5 stars$9.73+2.9%$34.10+250.5%-54.6%$837.27M$23.68M-2.52110Upcoming EarningsMENSJyong BiotechN/A$11.00+4.3%N/AN/A$836.33MN/A0.0031Positive NewsQuiet Period ExpirationIOVAIovance Biotherapeutics4.4649 of 5 stars$2.49+11.7%$12.22+390.9%-67.2%$831.49M$164.07M-2.01500Upcoming EarningsGap DownHigh Trading VolumeCRONCronos Group2.3244 of 5 stars$2.09+4.0%N/A-17.0%$806.07M$117.61M16.08450Upcoming EarningsXERSXeris Biopharma3.383 of 5 stars$5.14+0.6%$6.25+21.6%+121.4%$803.79M$203.07M-17.13290News CoveragePositive NewsUpcoming EarningsShort Interest ↑NUVBNuvation Bio2.2856 of 5 stars$2.36+2.4%$7.17+204.3%-37.4%$801.31M$7.87M-1.0060News CoverageUpcoming EarningsTRVITrevi Therapeutics2.4543 of 5 stars$6.82-0.6%$20.88+206.1%+136.5%$799.92MN/A-15.1620News CoveragePositive NewsUpcoming EarningsShort Interest ↑QUREuniQure2.4186 of 5 stars$14.50-3.3%$37.82+160.8%+83.0%$794.31M$27.12M-3.30500Trending NewsEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Mineralys Therapeutics Competitors Nurix Therapeutics Competitors Syndax Pharmaceuticals Competitors Jyong Biotech Competitors Iovance Biotherapeutics Competitors Cronos Group Competitors Xeris Biopharma Competitors Nuvation Bio Competitors Trevi Therapeutics Competitors uniQure Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESPR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
